|Bid||58.46 x 1200|
|Ask||58.70 x 1400|
|Day's Range||57.34 - 59.02|
|52 Week Range||26.40 - 74.81|
|Beta (3Y Monthly)||-0.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (30-Year Financial, Insider Trades) Brian B Hansen (insider trades) sold 15,000 shares of TNDM on 08/12/2019 at an average price of $62.97 a share. Continue reading...
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
In his final "Executive Decision" segment of Mad Money Wednesday night, Jim Cramer also checked in with Kim Blickenstaff, executive chairman at Tandem Diabetes Care , which posted strong earnings last week that sent shares up over 8% before giving back much of those gains by the close. Blickenstaff blamed the sudden reversal in their shares on global uncertainty. Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem.
Zacks.com featured highlights include: Crocs, IAC/InterActive, Fortinet, Tandem Diabetes and Cross Country
The medical device company got oh-so-close to erasing operating losses in Q2, but second-half growth will finally put the business in the black.
Today we will run through one way of estimating the intrinsic value of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by...
The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center
A closer look at the second-quarter GDP will help us to make three important inferences, which are expected to give guidance on the economy and stock market in the near term.
Tandem Diabetes (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EVP & CHIEF COMMERCIAL OFFICER of Tandem Diabetes Care Inc (TNDM) Brian B Hansen (insider trades) sold 13,031 shares of TNDM on 07/11/2019 at an average price of $70.04 a share. Continue reading...
Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM): Tandem Diabetes Care, Inc., a medical device company, designs, develops...
Tandem Diabetes Care (TNDM) plans to file an application seeking FDA approval for use of its Control-IQ technology in t: slim X2 insulin pumps for patients aged 14 and above.
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)First automated insulin delivery pumpTandem Diabetes Care’s (TNDM) automated insulin delivery system, t: slim X2 Insulin Pump with Basal-IQ technology,
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s pump demandIn the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%. The demand rose
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?(Continued from Prior Part)Tandem Diabetes Care’s revenue trajectoryIn its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue
Tandem Diabetes Care or Insulet: Which Is a Better Pick in June?Evolving insulin delivery landscapeUntil the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic (MDT) and Johnson & Johnson